-
1
-
-
74049141342
-
Intravitreal bevacizumab in pigmented rabbit eyes: Histological analysis 90 day after injection
-
J.C. Arraes, R.C. Tedesco, T.A. Arraes, E.B. Silva, A. Ventura, and M.P. Avila Intravitreal bevacizumab in pigmented rabbit eyes: histological analysis 90 day after injection Arq. Bras. Oftalmol. 72 2009 656 660
-
(2009)
Arq. Bras. Oftalmol.
, vol.72
, pp. 656-660
-
-
Arraes, J.C.1
Tedesco, R.C.2
Arraes, T.A.3
Silva, E.B.4
Ventura, A.5
Avila, M.P.6
-
2
-
-
77649324295
-
Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections
-
R.A. Adelman, Q. Zheng, and H.R. Mayer Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections J. Ocul. Pharmacol. Ther. 26 2010 105 110
-
(2010)
J. Ocul. Pharmacol. Ther.
, vol.26
, pp. 105-110
-
-
Adelman, R.A.1
Zheng, Q.2
Mayer, H.R.3
-
3
-
-
70349449737
-
Introduction: Understanding the role of angiogenesis and anti-angiogenic agents in age-related macular degeneration
-
S.B. Blessler Introduction: understanding the role of angiogenesis and anti-angiogenic agents in age-related macular degeneration Ophthalmology 116 2009 S1 S7
-
(2009)
Ophthalmology
, vol.116
-
-
Blessler, S.B.1
-
4
-
-
77149166301
-
Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells
-
S.V. Brar, R.K. Sharma, R.K. Murthy, and K.V. Chalam Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells J. Ocul. Pharmacol. Ther. 25 2009 507 511
-
(2009)
J. Ocul. Pharmacol. Ther.
, vol.25
, pp. 507-511
-
-
Brar, S.V.1
Sharma, R.K.2
Murthy, R.K.3
Chalam, K.V.4
-
5
-
-
77956968916
-
Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells
-
S.V. Brar, R.K. Sharma, R.K. Murthy, and K.V. Chalam Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells Mol. Vis. 16 2010 1848 1853
-
(2010)
Mol. Vis.
, vol.16
, pp. 1848-1853
-
-
Brar, S.V.1
Sharma, R.K.2
Murthy, R.K.3
Chalam, K.V.4
-
6
-
-
38449095942
-
Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment
-
C.K. Chan, and S.G. Lin Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment Eur. J. Ophthalmol. 17 2007 674 676
-
(2007)
Eur. J. Ophthalmol.
, vol.17
, pp. 674-676
-
-
Chan, C.K.1
Lin, S.G.2
-
7
-
-
67749116153
-
Bevacizumab is not toxic to retinal ganglion cells after repated intravitreal injection
-
C.K. Cheng, P.H. Peng, L.T. Tien, Y.J. Cai, C.F. Chen, and Y.J. Lee Bevacizumab is not toxic to retinal ganglion cells after repated intravitreal injection Retina 29 2009 306 312
-
(2009)
Retina
, vol.29
, pp. 306-312
-
-
Cheng, C.K.1
Peng, P.H.2
Tien, L.T.3
Cai, Y.J.4
Chen, C.F.5
Lee, Y.J.6
-
8
-
-
2442621619
-
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
-
N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat. Rev. Drug Discov. 3 2004 391 400
-
(2004)
Nat. Rev. Drug Discov.
, vol.3
, pp. 391-400
-
-
Ferrara, N.1
Hillan, K.J.2
Gerber, H.P.3
Novotny, W.4
-
9
-
-
33749632278
-
Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration
-
N. Ferrara, L. Damico, N. Shams, H. Lowman, and R. Kim Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870
-
(2006)
Retina
, vol.26
, pp. 859-870
-
-
Ferrara, N.1
Damico, L.2
Shams, N.3
Lowman, H.4
Kim, R.5
-
10
-
-
33846003083
-
Fine ultrastructure and biochemistry of PC12 cells: A comparative approach to understand neurotoxicity
-
F. Fornai, P. Lenzi, G. Lazzeri, M. Ferrucci, F. Fulceri, F.S. Giorgi, A. Falleni., S. Ruggieri, and A. Paparelli Fine ultrastructure and biochemistry of PC12 cells: a comparative approach to understand neurotoxicity Brain Res. 1129 2007 174 190
-
(2007)
Brain Res.
, vol.1129
, pp. 174-190
-
-
Fornai, F.1
Lenzi, P.2
Lazzeri, G.3
Ferrucci, M.4
Fulceri, F.5
Giorgi, F.S.6
Falleni, A.7
Ruggieri, S.8
Paparelli, A.9
-
11
-
-
81755161510
-
Protective effect of Bax ablation against cell loss in the retinal ganglion layer induced by optic nerve crush in transgenic mice
-
N. Goldenberg-Cohen, O. Dratviman-Storobinsky, Dadon Bar El, S. Cheporko, and Y. Hochhauser, E. Protective effect of Bax ablation against cell loss in the retinal ganglion layer induced by optic nerve crush in transgenic mice J. Neuroophthalmol. 31 2011 331 338
-
(2011)
J. Neuroophthalmol.
, vol.31
, pp. 331-338
-
-
Goldenberg-Cohen, N.1
Dratviman-Storobinsky, O.2
El, D.B.3
Cheporko, S.4
Hochhauser, E.Y.5
-
12
-
-
84856268421
-
Effects of intavitreal bevacizumab (Avastin) on the porcine retina
-
I. Iandiev, M. Francke, F. Makorov, M. Hollborn, S. Uhlmann, A. Wurm, A. Savvinov, L. Kohen, A. Reichenbach, P. Wiedemann, T. Pannicke, and A. Bringmann Effects of intavitreal bevacizumab (Avastin) on the porcine retina Graefes Arch. Clin. Exp. Ophthalmol. 249 2011 1821 1829
-
(2011)
Graefes Arch. Clin. Exp. Ophthalmol.
, vol.249
, pp. 1821-1829
-
-
Iandiev, I.1
Francke, M.2
Makorov, F.3
Hollborn, M.4
Uhlmann, S.5
Wurm, A.6
Savvinov, A.7
Kohen, L.8
Reichenbach, A.9
Wiedemann, P.10
Pannicke, T.11
Bringmann, A.12
-
13
-
-
80052771986
-
Visual results following intravitreal bevacizumab in neovascular age-related macular degeneration
-
K. Iqbal, J. Baig, A.Z. Jamil, H. Jamil, K. Mirza, and T. Khan Visual results following intravitreal bevacizumab in neovascular age-related macular degeneration J. Coll. Physicians Surg. Pak. 21 2011 535 538
-
(2011)
J. Coll. Physicians Surg. Pak.
, vol.21
, pp. 535-538
-
-
Iqbal, K.1
Baig, J.2
Jamil, A.Z.3
Jamil, H.4
Mirza, K.5
Khan, T.6
-
14
-
-
34548331324
-
Effect of anti-VEGF antibody on retinal ganglion cell in rats
-
A. Iriyama, Y.N. Chen, Y. Tamaki, and Y. Yanagi Effect of anti-VEGF antibody on retinal ganglion cell in rats Br. J. Ophthalmol. 91 2007 1230 1233
-
(2007)
Br. J. Ophthalmol.
, vol.91
, pp. 1230-1233
-
-
Iriyama, A.1
Chen, Y.N.2
Tamaki, Y.3
Yanagi, Y.4
-
15
-
-
77956058023
-
In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells
-
M.Y. Kahook, and D.A. Ammar In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells J. Glaucoma 19 2010 437 441
-
(2010)
J. Glaucoma
, vol.19
, pp. 437-441
-
-
Kahook, M.Y.1
Ammar, D.A.2
-
16
-
-
84866514869
-
Impact of intravitreal injection of Bevacizumab (Avastin) on Rabbit's Choroid and Retina
-
S. Karawya, D.G. Said, M.M. Salaheldin, and I. Zaky Impact of intravitreal injection of Bevacizumab (Avastin) on Rabbit's Choroid and Retina Middle East Afr. J. Ophthalmol. 15 2008 67 72
-
(2008)
Middle East Afr. J. Ophthalmol.
, vol.15
, pp. 67-72
-
-
Karawya, S.1
Said, D.G.2
Salaheldin, M.M.3
Zaky, I.4
-
17
-
-
79961239961
-
Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma
-
M. Kubota-Taniai, T. Oshitari, M. Handa, T. Baba, J. Yotsukura, and S. Yamamoto Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma J. Clin. Ophthalmol 5 2011 1051 1055
-
(2011)
J. Clin. Ophthalmol
, vol.5
, pp. 1051-1055
-
-
Kubota-Taniai, M.1
Oshitari, T.2
Handa, M.3
Baba, T.4
Yotsukura, J.5
Yamamoto, S.6
-
18
-
-
57949101556
-
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularisation? Graefes Arch
-
F. Lu, and R.A. Adelman Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularisation? Graefes Arch Clin. Exp. Ophthalmol. 247 2009 171 177
-
(2009)
Clin. Exp. Ophthalmol.
, vol.247
, pp. 171-177
-
-
Lu, F.1
Adelman, R.A.2
-
19
-
-
34547167572
-
For the Tübingen bevacizumab study group. The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator
-
M. Lüke, K. Januschowski, M. Warga, J. Beutel, M. Leitritz, F. Gelisken, S. Grisanti, T. Schneider, C. Lüke, K.U. Bartz-Schmidt, and P. Szurman for the Tübingen bevacizumab study group. The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator Br. J. Ophthalmol. 91 2007 1077 1082
-
(2007)
Br. J. Ophthalmol.
, vol.91
, pp. 1077-1082
-
-
Lüke, M.1
Januschowski, K.2
Warga, M.3
Beutel, J.4
Leitritz, M.5
Gelisken, F.6
Grisanti, S.7
Schneider, T.8
Lüke, C.9
Bartz-Schmidt, K.U.10
Szurman, P.11
-
20
-
-
33646438886
-
Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment
-
R.K. Maturi, L.A. Bleau, and D.L. Wilson Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment Retina. 26 2006 270 274
-
(2006)
Retina.
, vol.26
, pp. 270-274
-
-
Maturi, R.K.1
Bleau, L.A.2
Wilson, D.L.3
-
21
-
-
79958706138
-
Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: Ranibizumab and bevacizumab
-
C.H. Meyer, and F.G. Holz Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab Eye 25 2011 661 672
-
(2011)
Eye
, vol.25
, pp. 661-672
-
-
Meyer, C.H.1
Holz, F.G.2
-
22
-
-
77957360007
-
VEGF-antagonists decrease barrier function of retinal pigment epithelium in vitro-possible participation of intracellular glutathione
-
Y. Miura, A. Kletter, and J. Roider VEGF-antagonists decrease barrier function of retinal pigment epithelium in vitro-possible participation of intracellular glutathione Invest. Ophthalmol. Vis. Sci. 51 2010 4848 4855
-
(2010)
Invest. Ophthalmol. Vis. Sci.
, vol.51
, pp. 4848-4855
-
-
Miura, Y.1
Kletter, A.2
Roider, J.3
-
23
-
-
84859906379
-
Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors
-
A.C. Myers, A.M. Lövestam, A. Bruun, F. Ghosh, S. Andréasson, and V. Ponjavic Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors Curr. Eye Res. 37 2012 399 407
-
(2012)
Curr. Eye Res.
, vol.37
, pp. 399-407
-
-
Myers, A.C.1
Lövestam, A.M.2
Bruun, A.3
Ghosh, F.4
Andréasson, S.5
Ponjavic, V.6
-
24
-
-
68349101301
-
Brn3a as a marker of retinal ganglion cells: Qualitative and quantitative time course studies in naive and optic nerve-injured retinas
-
F.M. Nadal-Nicolás, M. Jiménez-López, P. Sobrado-Calvo, L. Nieto-López, I. Cánovas-Martínez, M. Salinas-Navarro, M. Vidal-Sanz, and M. Agudo Brn3a as a marker of retinal ganglion cells: qualitative and quantitative time course studies in naive and optic nerve-injured retinas Invest Ophthalmol. Vis. Sci. 50 2009 3860 3868
-
(2009)
Invest Ophthalmol. Vis. Sci.
, vol.50
, pp. 3860-3868
-
-
Nadal-Nicolás, F.M.1
Jiménez-López, M.2
Sobrado-Calvo, P.3
Nieto-López, L.4
Cánovas-Martínez, I.5
Salinas-Navarro, M.6
Vidal-Sanz, M.7
Agudo, M.8
-
25
-
-
70449530860
-
Time-course of the retinal nerve fibre layer degeneration after complete intra-orbital optic nerve transection or crush: A comparative study
-
G. Parrilla-Reverter, M. Agudo, F. Nicolas, L. Alarcón- Martínez, M. Jiménez-López, M. Salinas-Navarro, P. Sobrado-Calvo, J.M. Bernal-Garro, M.P. Villegas-Pérez, and M. Vidal-Sanz Time-course of the retinal nerve fibre layer degeneration after complete intra-orbital optic nerve transection or crush: a comparative study Vision Res. 49 2009 2808 2825
-
(2009)
Vision Res.
, vol.49
, pp. 2808-2825
-
-
Parrilla-Reverter, G.1
Agudo, M.2
Nicolas, F.3
Alarcón-Martínez, L.4
Jiménez-López, M.5
Salinas-Navarro, M.6
Sobrado-Calvo, P.7
Bernal-Garro, J.M.8
Villegas-Pérez, M.P.9
Vidal-Sanz, M.10
-
26
-
-
79954598744
-
Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors
-
G. Pellé, N. Shweke, J.P. Duong Van Huyen, L. Tricot, S. Hessaïne, V. Frémeaux-Bacchi, C. Hiesse, and M. Delahousse Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors Am. J. Kidney Dis. 57 2011 756 759
-
(2011)
Am. J. Kidney Dis.
, vol.57
, pp. 756-759
-
-
Pellé, G.1
Shweke, N.2
Duong Van Huyen, J.P.3
Tricot, L.4
Hessaïne, S.5
Frémeaux-Bacchi, V.6
Hiesse, C.7
Delahousse, M.8
-
27
-
-
70949085553
-
A novel biomarker for retinal degeneration: Vitreous body neurofilament proteins
-
A. Petzold, A. Junemann, K. Rejdak, T. Zarnowski, S. Thaler, P. Grieb, F.E. Kruse, E. Zrenner, and R. Rejdak A novel biomarker for retinal degeneration: vitreous body neurofilament proteins J. Neural Transm. 116 2009 1601 1606
-
(2009)
J. Neural Transm.
, vol.116
, pp. 1601-1606
-
-
Petzold, A.1
Junemann, A.2
Rejdak, K.3
Zarnowski, T.4
Thaler, S.5
Grieb, P.6
Kruse, F.E.7
Zrenner, E.8
Rejdak, R.9
-
28
-
-
1842609542
-
Retinal toxicity of intravitreal tenecteplase in the rabbit
-
S.A. Rowley, S. Vijayasekaran, P.K. Yu, I.L. McAllister, and D.Y. Yu Retinal toxicity of intravitreal tenecteplase in the rabbit Br. J. Ophthalmol. 88 2004 573 578
-
(2004)
Br. J. Ophthalmol.
, vol.88
, pp. 573-578
-
-
Rowley, S.A.1
Vijayasekaran, S.2
Yu, P.K.3
McAllister, I.L.4
Yu, D.Y.5
-
29
-
-
47649125703
-
Complications in patients after intravitreal injection of bevacizumab
-
C. Shima, H. Sakaguchi, F. Gomi, M. Kamei, Y. Ikuno, Y. Oshima, M. Sawa, M. Tsujikawa, S. Kusaka, and Y. Tano Complications in patients after intravitreal injection of bevacizumab Acta Ophthalmol. 86 2008 372 376
-
(2008)
Acta Ophthalmol.
, vol.86
, pp. 372-376
-
-
Shima, C.1
Sakaguchi, H.2
Gomi, F.3
Kamei, M.4
Ikuno, Y.5
Oshima, Y.6
Sawa, M.7
Tsujikawa, M.8
Kusaka, S.9
Tano, Y.10
-
30
-
-
33750285956
-
Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells
-
M.S. Spitzer, B. Wallenfels-Thilo, A. Sierra, E. Yoeruek, S. Peters, S. Henke-Fahle, K.U. Bartz-Schmidt, and P. Szurman Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells Br. J. Ophthalmol. 90 2006 1316 1321
-
(2006)
Br. J. Ophthalmol.
, vol.90
, pp. 1316-1321
-
-
Spitzer, M.S.1
Wallenfels-Thilo, B.2
Sierra, A.3
Yoeruek, E.4
Peters, S.5
Henke-Fahle, S.6
Bartz-Schmidt, K.U.7
Szurman, P.8
-
31
-
-
77954629812
-
Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage
-
S. Thaler, M. Fiedorowicz, T.J. Choragiewicz, S. Bolz, A. Tura, S. Henke-Fahle, E. Yoeruek, E. Zrenner, K.U. Bartz-Schmidt, F. Ziemssen, and F. Schuettauf Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage Acta Ophthalmol. 88 2010 e170 e176
-
(2010)
Acta Ophthalmol.
, vol.88
-
-
Thaler, S.1
Fiedorowicz, M.2
Choragiewicz, T.J.3
Bolz, S.4
Tura, A.5
Henke-Fahle, S.6
Yoeruek, E.7
Zrenner, E.8
Bartz-Schmidt, K.U.9
Ziemssen, F.10
Schuettauf, F.11
-
32
-
-
79951525187
-
Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease
-
M. Tolentino Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease Surv. Ophthalmol 56 2011 95 113
-
(2011)
Surv. Ophthalmol
, vol.56
, pp. 95-113
-
-
Tolentino, M.1
-
33
-
-
84859433783
-
Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration
-
J.J. Tseng, S.K. Vance, K.E. Della Torre, L.S. Mendonca, M.J. Cooney, J.M. Klancnik, J.A. Sorenson, and K.B. Freund Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration J. Glaucoma 21 2012 241 247
-
(2012)
J. Glaucoma
, vol.21
, pp. 241-247
-
-
Tseng, J.J.1
Vance, S.K.2
Della Torre, K.E.3
Mendonca, L.S.4
Cooney, M.J.5
Klancnik, J.M.6
Sorenson, J.A.7
Freund, K.B.8
-
34
-
-
34548279498
-
Safety profile of bevacizumab on cultured human corneal cells
-
E. Yoeruek, M.S. Spitzer, O. Tatar, S. Aisenbrey, K.U. Bartz-Schmidt, and P. Szurman Safety profile of bevacizumab on cultured human corneal cells Cornea 26 2007 977 982
-
(2007)
Cornea
, vol.26
, pp. 977-982
-
-
Yoeruek, E.1
Spitzer, M.S.2
Tatar, O.3
Aisenbrey, S.4
Bartz-Schmidt, K.U.5
Szurman, P.6
-
35
-
-
47749112506
-
Safety monitoring in bevacizumab (Avastin) treatment: Retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients
-
F. Ziemssen, M. Lüke, A. Messias, J. Beutel, O. Tatar, E. Zrenner, and K.U. Bartz-Schmidt Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients Int. Ophthalmol. 28 2008 101 109
-
(2008)
Int. Ophthalmol.
, vol.28
, pp. 101-109
-
-
Ziemssen, F.1
Lüke, M.2
Messias, A.3
Beutel, J.4
Tatar, O.5
Zrenner, E.6
Bartz-Schmidt, K.U.7
|